PCRI Celebrates FDA Approval of XOCOVA®

We're excited to celebrate an important milestone in clinical research—the FDA approval of XOCOVA® (ensitrelvir), the first and only oral medication approved in the United States to help prevent COVID-19 following exposure.

---

XOCOVA provides a new option for individuals who have recently been exposed to the virus and the team at Premier Clinical Research Institute (PCRI) is proud to have been one of the research sites that participated in the studies supporting the development of this groundbreaking treatment.

Every clinical trial represents a collaborative effort between study participants, sponsors, investigators, and research teams, and we're honored to have contributed to bringing this preventative medication to patients.

This achievement reflects the dedication of our physicians, coordinators, and staff, whose commitment to high-quality clinical research helps turn promising therapies into FDA-approved treatments. Most importantly, we're grateful to the volunteers who chose to participate in the clinical trial—without them, medical breakthroughs like this would not be possible.

The approval of XOCOVA is another reminder of the life-changing impact of clinical research, and we're proud that Premier Clinical Research Institute was part of the journey on another successful clinical trial. We look forward to continuing to advance innovative research and helping bring treatments to the patients who need them most. We will always work towards staying true to our motto "Research Today For A Healthier Tomorrow"

---

Here's to celebrating this achievement—and to the many more breakthroughs still to come!

To read more about it, check out this article: Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure| Shionogi Inc.